Steven Rosenberg has been a cancer immunotherapy trailblazer. In 2023, his research finally proved to be a commercial success: Yescarta, the blood cancer therapy he developed in partnership with biotech Kite Pharma (now part of Gilead), is the first CAR-T treatment to bring in more than $1 billion in annual sales. Rosenberg was also awarded the National Medal of Technology and Innovation by President Biden in late 2023, a nod not just to his past achievements but the work that lies ahead — such as his current research on how tumor-infiltrating lymphocytes, or TILs, in immune cells may be used to shrink tumors in people with metastatic breast cancer.
Industry
Location
-
Bethesda, Md.
